


THE 27TH PLANOVA™ WORKSHOP

SEATTLE
OCT. 22-23, 2026



Program at a Glance



The agenda will be finalized a few weeks prior to the event.

Join us at the Workshop in Seattle!

Register to attend

The 27th Planova™ Workshop

\$200 per person

<https://www.accelevents.com/e/planova-workshop-2026>

[Click here to Register](#)

Book your hotel (marriott.com)

Seattle Marriott Waterfront

2100 Alaskan Way, Seattle, WA 98121

For inquiries, please reach out to us at WS2026@ak-bio.com

THE 27TH PLANOVA™ WORKSHOP

SEATTLE
OCT. 22-23, 2026



June 23, 2026

Dear Valued Customers,

We are pleased to invite you to attend the upcoming Planova™ Workshop.

The 27th Planova™ Workshop
Seattle Marriott Waterfront
Seattle, WA, USA
October 22-23, 2026
Reception Dinner on Wednesday, October 21

In the city where innovations emerge and go on to change the world, we look forward to sharing the latest developments from our global team as well as users of Planova™ virus removal filters and BioOptimal™ hollow fiber microfilters.

At the 27th Planova™ Workshop, distinguished speakers will share their experiences and expertise in upstream and downstream process development, along with regulatory updates. Attendees of our workshop are bioprocessing professionals, from scientists to process engineers and managers, all focused on the purification and pathogen safety of biopharmaceuticals.

Registration for attending the Workshop and related events is open. Workshop participants are welcome to utilize a special rate at the Seattle Marriott Waterfront hotel during and around the Workshop dates. Links to both registration and hotel booking are available here:

<https://www.accelevents.com/e/planova-workshop-2026>

We look forward to you joining us and the confirmed chairs and speakers shown on the next page. More information will be forthcoming in our next announcement and on our Workshop website.

Sincerely,

Sachio Asanagi
Executive Vice President
Asahi Kasei Bioprocess America, Inc.



THE 27TH PLANOVA™ WORKSHOP

SEATTLE | OCT. 22-23, 2026

Scientific Program Preview

Confirmed Chairs

Kevin Brower, Ph.D.

Global Head, Purification Development, Mammalian Platform, Sanofi

Valerie Cusick

Director, Preclinical Manufacturing and Process Development (PMPD), Regeneron

Angela Lewandowski, Ph.D.

Head, Global Downstream and Harvest Development, Biologics Development, Bristol Myers Squibb

Sessions and Presentations (tentative)

Session 1: Regulatory and Fundamentals

Enhancing Adventitious Agent Safety: Prior Knowledge and Platform Approaches in the Era of ICH Q5A (R2)

Andy Bailey, Ph.D., CEO, Bionique Testing Laboratories

Viral Clearance Capability of Monoclonal Antibody Purification

Kang Cai, Ph.D., Director, Biopharmaceutical Development, AstraZeneca

Session 2: Virus Filtration

Advancing Virus Filtration: Pilot and GMP Implementation of Planova FG1 across Diverse Antibody Therapeutics

Marcus Fiadeiro, Associate Director, Purification/Mammalian Platform, Sanofi

Planova FG1 Viral Filter Application: Enabling Robust Viral Clearance for Diverse Antibody Formats

Sam Marzolf, Scientist II, Downstream Process Development, Lundbeck

Viral Filtration in an Intensified Process

Sean O'Donnell, Ph.D., Executive Director, Virology and Purification Development, Eli Lilly and Company

Transition from Planova 20N to S20N Viral Filter

Lindsay Pautsch, Scientist II, Purification Process Development, Just-Evotec Biologics

A Comparative Evaluation of the Planova S20N and 20N Virus Filters

Russell Van Buskirk, Senior Principal Scientist, BioProcess Development, Amgen

Understanding Virus Entrapment in Virus Filtration Membranes (Joint Presentation)

Ranil Wickramasinghe, Ph.D., Distinguished Professor, Ralph E Martin Department of Chemical Engineering, University of Arkansas

and

Xianghong Qian, Ph.D. Professor, Department of Biomedical Engineering, University of Arkansas



THE 27TH PLANOVA™ WORKSHOP

SEATTLE | OCT. 22-23, 2026

Scientific Program Preview (continued)

Session 3: Continuous Processes and Perfusion

Mitigating Cell Retention Filter Fouling for 2000 L High Density Perfusion

Naomichi Hikichi, Scientist, Process Engineering & Technology Center,
FUJIFILM Corporation

Scaling and Trends in TFF Perfusion Processes

Patrick Romann, Ph.D., Bioprocess Innovation Manager, R&D, Levitronix

Development of a Continuous Virus Filtration Process

Etienne Utiger, Senior Scientist, Biopharmaceutical Development, AstraZeneca

Session 4: New Technologies and New Applications

Presentations to be Announced